PDCD1 and neoplasm: Significant barriers, including tumor-mediated immune suppression (e.g., via IL-10 and TGF-β), downregulation of antigen expression, regulatory T-cell dominance, and robust checkpoint pathways (e.g., PD-1/PD-L1), impede the full potential of DC-based therapies (134, 135).